Join us for a virtual KOL event with Akari Therapeutics, featuring Elias Reichel, MD (Tufts University School of Medicine) who will discuss the treatment landscape in geographic atrophy (GA) and the potential for long-acting PAS-nomacopan to address significant unmet needs. Akari’s lead asset is investigational nomacopan, a novel bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4).

The Akari management team will present an overview and update on the pre-clinical development program investigating long-acting PAS-nomacopan as a potential treatment for GA.

A live question and answer session will follow the formal presentations.